Our dynamic team is dedicated to uncovering the intricate roles of SUMOylation in health and pathogenesis, with a strong focus on advancing cell and disease biology and drug discovery. We conduct curiosity-driven fundamental research to dissect the functions of SUMOylation in key cellular processes and pathogenesis. To achieve this, we employ multidisciplinary approaches, including cell biology, biochemistry, high-resolution imaging, proteomics, and transgenic animal models of disease.
Our lab is particularly interested in neurodegeneration and the development of novel therapeutics for neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS). ALS is a devastating neurodegenerative disease characterized by the degeneration of motor neurons in the brainstem and spinal cord, typically leading to death within 3 to 4 years of symptom onset. It is the most common motor neuron disease in humans and the third most prevalent neurodegenerative disorder after Alzheimer’s and Parkinson’s diseases, with very limited treatment options available.
At the basic science level, we investigate the role of sumoylation in ALS pathogenesis to gain insights into the mechanisms of neurodegeneration in ALS patients. At the translational level, our long-term goal is to enhance the clearance of toxic proteins from the motor neurons of ALS patients. To this end, we are currently exploring the potential of targeting sumoylation as a therapeutic strategy.
For more information, please visit the website of our research group.
